Gabapentin Capsule
Product Images NDC 71335-3109

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-3109). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cockcroft And Gault Equation (979787f3 7230 4586 862f 5c05686b8a43 01)

This text provides a formula for estimating creatinine clearance (CLCr) based on age, weight, and serum creatinine levels. The formula involves subtracting the age in years from 140, multiplying by weight in kilograms, and then dividing by 72 multiplied by the serum creatinine level in mg/dl. For female patients, the result is then multiplied by 0.85. This calculation is commonly used in clinical settings to assess renal function.*

FDA Label Image

Image (979787f3 7230 4586 862f 5c05686b8a43 02)

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (979787f3 7230 4586 862f 5c05686b8a43 03)

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (979787f3 7230 4586 862f 5c05686b8a43 04)

This is a table showing the mean pain scores for different treatments over several weeks. The treatments include a placebo, gabapentin at a dose of 1800 mg/day, and gabapentin at a dose of 2400 mg/day. The baseline and scores for weeks 1 to 7 are provided for evaluation.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥ 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (979787f3 7230 4586 862f 5c05686b8a43 05)

This text provides data on the proportion of responders (patients with a 50-100% reduction in pain score) in controlled PHN studies. The table shows the results of Study 1 and Study 2, with percentages indicating the proportion of responders in each study. Additionally, there is a note indicating statistical significance (*p<0.001) for the comparison.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥ 12 Years Of Age With Partial Seizures (979787f3 7230 4586 862f 5c05686b8a43 06)

Not available*

FDA Label Image

Label (Lbl713353109)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.